Article
Data Migration and Data Integrity — The Hidden Risk in System Transitions
Every time a pharmaceutical company migrates data from a legacy GMP system to a new platform — LIMS, ELN, quality management system, stability software — it creates a…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Data Migration and Data Integrity — The Hidden Risk in System Transitions
Every time a pharmaceutical company migrates data from a legacy GMP system to a new platform — LIMS, ELN, quality management system, stability software — it creates a…
Article
LNP Future Trends: SORT Targeting, Next-Gen Ionizable Lipids, Gene Editing
Every LNP program currently in clinical development was designed on the mechanistic understanding established between 2010 and 2020. That framework produced patisiran, the COVID-19 mRNA vaccines, and a…
Article
Supplier Qualification — GMP Requirements That 483s Expose
When FDA issues a 483 observation for inadequate control of materials, the citation almost always traces back to a supplier qualification program that checked a box rather than…
Article
mRNA Therapeutics CMC: Beyond the Vaccine Paradigm
The COVID-19 mRNA vaccine programs created a widespread assumption that the CMC framework developed for mRNA vaccines applies directly to mRNA therapeutics. It does not — not entirely…
Article
Annual Product Review — From Compliance Exercise to CMC Intelligence
The Annual Product Review — or Product Quality Review as EU GMP calls it — is one of the most universally produced and most universally underutilized documents in…
Article
siRNA-LNP CMC: Regulatory Lessons from Onpattro That Every Program Needs
Patisiran (Onpattro) was approved by FDA on August 10, 2018 — the first RNA interference drug product to receive regulatory approval anywhere in the world, delivered in an…
Article
Change Control Risk Classification — The Decision Tree That Prevents Holds
A post-approval manufacturing change that required a Prior Approval Supplement but was submitted as a Changes Being Effected in 30 Days notification is not a submission strategy —…
Article
PEGylation in LNPs: Anti-PEG Antibodies and the CMC Risk Strategy
PEG-lipid is a structural component of every approved LNP drug product. Without it, the LNP as a systemic delivery vehicle does not function. And yet PEG-lipid brings with…
Article
Specification Setting — ICH Q6A Applied to Real CMC Submissions
The most common reason FDA issues a Complete Response Letter for CMC deficiencies related to specifications is not that the acceptance criteria are wrong — it is that…
Article
Regulatory Navigation: CDER vs CBER, EMA, and the Nanotechnology Landscape
"The regulatory framework for lipid nanoparticle drug products is still being built in real time. Understanding which regulatory framework applies to your LNP program — and how to…
Article
ICH Q2(R2) Analytical Method Validation — Navigating the Updated Standard
ICH Q2(R2) reached ICH Step 4 in 2023 and was issued as final FDA guidance in March 2024 and introduced changes to analytical method validation that go beyond…
Article
LNP Process Validation: Applying FDA Three-Stage Framework to Microfluidics
The FDA's 2011 Process Validation guidance applies to LNP manufacturing. What requires careful thinking is how the three-stage framework maps onto a process where the critical transformation happens…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.